Showing results (891-900 of 3,716) with videos related to
Sort By:
Pageof 372
Investigational New Drugs|May 1, 2025
An investigation of extended-interval dosing of atezolizumab in Japanese patients with advanced solid tumors: safety and pharmacokinetics of a dose of 1680 mg every 4 weeksShunsuke Kondo, Shigehisa Kitano, Jun Sato, et al.Investigational New Drugs|April 15, 2025
Bispecific antibody targeting CD155 mediates T-cell immunotherapy against human gynecological malignanciesLi Ma, Juan Ma, Dingqing Feng, et al.Investigational New Drugs|March 17, 2025
Evaluation of the anti-leukemia activity and underlying mechanisms of the novel perinucleolar compartment inhibitor CTI-2 in acute myeloid leukemiaAnran Li, Mingmin Yu, Yue Zhao, et al.Investigational New Drugs|June 5, 2024
A first-in-human phase I trial of daily oral zelenirstat, a N-myristoyltransferase inhibitor, in patients with advanced solid tumors and relapsed/refractory B-cell lymphomasRandeep Sangha, Rahima Jamal, Jennifer Spratlin, et al.Investigational New Drugs|June 6, 2024
Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study)Kazufumi Kobayashi, Sadahisa Ogasawara, Ei Itobayashi, et al.Investigational New Drugs|May 24, 2024
Effect of PAWI-2 on pancreatic cancer stem cell tumorsJohn R Cashman, Emily A CashmanInvestigational New Drugs|May 17, 2024
In vitro results with minimal blood toxicity of a combretastatin A4 analogueCamila Chagas, Jaqueline Vital Mansano, Emerson Barbosa da Silva, et al.Investigational New Drugs|May 3, 2024
Toxicity burden patterns of MET-selective tyrosine kinase inhibitors: evidence from real-world pharmacovigilanceWenjie Li, Wei WangInvestigational New Drugs|December 15, 2023
Effects of food and ethnicity on the pharmacokinetics of venadaparib, a next-generation PARP inhibitor, in healthy Korean, Caucasian, and Chinese male subjectsHyun Chul Kim, Eunsol Yang, Soyoung Lee, et al.Investigational New Drugs|June 19, 2026
Characterizing the post-market safety profile of cemiplimab: a pharmacovigilance study of the FDA adverse events reporting system databaseConnor FreyPageof 372